| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 939 | 2018 |
| Eculizumab in aquaporin-4–positive neuromyelitis optica spectrum disorder SJ Pittock, A Berthele, K Fujihara, HJ Kim, M Levy, J Palace, I Nakashima, ... New England Journal of Medicine 381 (7), 614-625, 2019 | 644 | 2019 |
| Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind … JF Howard, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... The Lancet Neurology 16 (12), 976-986, 2017 | 583 | 2017 |
| Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ... Jama 321 (2), 175-187, 2019 | 461 | 2019 |
| Defining secondary progressive multiple sclerosis J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ... Brain 139 (9), 2395-2405, 2016 | 392 | 2016 |
| Defining reliable disability outcomes in multiple sclerosis T Kalincik, G Cutter, T Spelman, V Jokubaitis, E Havrdova, D Horakova, ... Brain 138 (11), 3287-3298, 2015 | 201 | 2015 |
| Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis S Muppidi, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... Muscle & nerve 60 (1), 14-24, 2019 | 186 | 2019 |
| Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis T Kalincik, D Horakova, T Spelman, V Jokubaitis, M Trojano, A Lugaresi, ... Annals of Neurology 77 (3), 425-435, 2015 | 186 | 2015 |
| Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study T Kalincik, JWL Brown, N Robertson, M Willis, N Scolding, CM Rice, ... The Lancet Neurology 16 (4), 271-281, 2017 | 171 | 2017 |
| Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study A Altintas, B Petek, N Isik, M Terzi, F Bolukbasi, M Tavsanli, S Saip, C Boz, ... Multiple Sclerosis Journal 18 (10), 1448-1453, 2012 | 155 | 2012 |
| Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis A He, T Spelman, V Jokubaitis, E Havrdova, D Horakova, M Trojano, ... JAMA neurology 72 (4), 405-413, 2015 | 128 | 2015 |
| Towards personalized therapy for multiple sclerosis: prediction of individual treatment response T Kalincik, A Manouchehrinia, L Sobisek, V Jokubaitis, T Spelman, ... Brain 140 (9), 2426-2443, 2017 | 114 | 2017 |
| Frontal functions in young patients with essential tremor: a case comparison study HA Şahin, M Terzi, S Uçak, O Yapıcı, T Başoğlu, M Onar The Journal of neuropsychiatry and clinical neurosciences 18 (1), 64-72, 2006 | 100 | 2006 |
| Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis C Tao, S Simpson, I Van Der Mei, L Blizzard, E Havrdova, D Horakova, ... Journal of Neurology, Neurosurgery & Psychiatry 87 (12), 1343-1349, 2016 | 98 | 2016 |
| Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis T Kalincik, EK Havrdova, D Horakova, G Izquierdo, A Prat, M Girard, ... Journal of Neurology, Neurosurgery & Psychiatry 90 (4), 458-468, 2019 | 90 | 2019 |
| Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial BAC Cree, G Cutter, JS Wolinsky, MS Freedman, G Comi, G Giovannoni, ... The Lancet Neurology 19 (12), 988-997, 2020 | 81 | 2020 |
| Risk of secondary progressive multiple sclerosis: a longitudinal study A Fambiatos, V Jokubaitis, D Horakova, E Kubala Havrdova, M Trojano, ... Multiple Sclerosis Journal 26 (1), 79-90, 2020 | 80 | 2020 |
| Effect of disease-modifying therapy on disability in relapsing-remitting multiple sclerosis over 15 years T Kalincik, I Diouf, S Sharmin, C Malpas, T Spelman, D Horakova, ... Neurology 96 (5), e783-e797, 2021 | 73 | 2021 |
| Changes in bone mineral density and bone metabolism markers in premenopausal women with multiple sclerosis and the relationship to clinical variables T Terzi, M Terzi, B Tander, F Cantürk, M Onar Journal of Clinical Neuroscience 17 (10), 1260-1264, 2010 | 72 | 2010 |
| Long‐term safety and efficacy of Eculizumab in Aquaporin‐4 IgG‐positive NMOSD DM Wingerchuk, K Fujihara, J Palace, A Berthele, M Levy, HJ Kim, ... Annals of neurology 89 (6), 1088-1098, 2021 | 70 | 2021 |
